Clinical Trial Update: Safety of REL-1017 for Major Depressive Disorder [Phase 3]

View source ↗

Summary

Relmada Therapeutics reported completion and posting of the Phase 3 safety results for REL-1017 in major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• REL-1017

Snippet

Sponsor: Relmada Therapeutics, Inc. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2024-08-09